F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US

F2G Ltd, a biopharmaceutical company, has announced a $100 million financing round to develop a novel oral antifungal therapy for rare fungal infections. The funding is led by AMR Action Fund and co-led by ICG, with participation from Novo Holdings, Advent Life Sciences, Sofinnova Partners, Forbion, Blue Owl Healthcare Opportunities, Morningside Ventures, Brace Pharmaceuticals, and Merifin Capital. The proceeds will enable F2G to complete late-stage development, seek regulatory approval, and prepare for commercialization in the US of olorofim, a novel oral antifungal therapy for invasive aspergillosis and other invasive fungal infections. The financing is subject to customary Foreign Direct Investment (FDI) clearance by local authorities in Austria and is expected to close in the fourth quarter of 2024. The company aims to address the unmet medical need for advanced antifungal treatments and address the growing threat of fungal infections.